Skip to main content
. 2023 Sep 7;23:302. doi: 10.1186/s12871-023-02262-2

Table 3.

Univariate analysis of potential associated factors of emergence delirium

Characteristics With ED
(N = 135)
Without ED
(N = 47)
P-value
Baseline characteristics
Age, year 54(18–82) 45(19–76) 0.028
Gender, N (%) 0.001
Male 71(52.6) 38(80.9)
Female 64(47.4) 9(19.2)
BMI, kg/m2 24.2(21.5, 26.5) 25.9(22.7, 27.7) 0.042
MAP at admission, mmHg 97.8 (12.1) 100 (10.6) 0.180
ASA, N (%) > 0.999
I 83 (61.5) 29(61.7)
II 52(38.5) 18(38.3)
Head ache, N (%) 0.183
Negative 67(69.1) 27(81.8)
Positive 30(30.9) 6(18.2)
Nasal obstruction, N (%) 0.306
Negative 73(54.1) 30(63.8)
Positive 62(45.9) 17(36.2)
Nasal obstruction side, N (%) 0.750
Single 17(38.6) 6(46.2)
Both 27(61.4) 7(53.8)
Nasal obstruction description, N (%) 0.491
Intermittent 7(87.5) 2(66.7)
Persistent 1(12.5) 1(33.3)
Nasal obstruction with nasal polyps, N (%) 0.270
Negative 37(59.7) 7(41.2)
Positive 25(40.3) 10(58.8)
Nasal obstruction with septum deviation, N (%) 0.004
Negative 54(87.1) 9(52.9)
Positive 8(12.9) 8(47.1)
Chronic rhinosinusitis with nasal polyps, N (%) 0.354
Negative 96(71.1) 20(63.8)
Positive 39(28.9) 17(36.2)
Current smoker, N (%) 0.011
Negative 114(83.8) 31(66.0)
Positive 21(16.2) 16(34.0)
History of HBP, N (%) 0.686
Negative 104(77.0) 35(74.5)
Positive 31(23.0) 12(25.5)
History of DM, N (%) 0.525
Negative 123(91.1) 45(95.7)
Positive 12(8.89) 2(4.26)
Preoperative measurements
Nasal splint, N/P 0.004
Negative 58(43.0) 32(68.1)
Positive 77(57.0) 15(31.9)
HR before Nasal splint, bpm 76.0(68.0, 82.0) 76.0(68.0, 81.0) 0.918
MAP before Nasal splint, mmHg 94.10(11.051) 94.9(11.6) 0.933
SpO2 before Nasal splint, % 99.0(98.0, 99.0) 99.0(98.0, 99.0) 0.512
 h after Nasal splint, bpm 76.0(65.0, 81.0) 78.0 (69.5, 79.0) 0.903
MAP after Nasal splint, mmHg 93.3 (10.4) 91.7 (13.3) 0.625
SpO2 after Nasal splint, % 99.0(98.0, 99.0) 99.0(98.0, 99.0) 0.353
Intraoperative measurements
Duration of surgery, min 45.0(30.0, 60.0) 45.0(25.0, 70.0) 0.970
Duration of anesthesia, min 64.0(50.0, 84.0) 65.0(49.0, 89.0) 0.931
Intraoperative sufentanil dosage, µg 20.0(15.0, 23.0) 20.0(15.0, 20.0) 0.567
Dosage of sufentanil per unit anesthesia time, µg/min 0.27(0.22, 0.33) 0.27 (0.22, 0.33) 0.660
FESS with septoplasty, N (%) 0.036
Without 123(91.1) 37(78.2)
With 12(8.89) 10(21.3)
Nasal package, N (%) 0.851
Negative 37(27.4) 12(25.5)
Positive 98(72.6) 35(74.5)
Package Side, N (%) 0.805
Single 21(26.6) 8(29.6)
Both 58(73.4) 19(70.4)
Postoperative measurements
Minutes to extubation, min 17.0(12.0, 19.0) 16.0(12.0, 17.0) 0.816
Medication in PACU, N (%) 0.016
Negative 135(100) 44(93.6)
Positive 0(0) 3(6.38)
Time to left PACU, min 54.0(46.0,58.0) 58.0(49.0,60.0) 0.003
NRS in PACU, Sum 0(0, 6.00) 0(0, 6.00) 0.619
 h when left PACU, bpm 70.0(63.0, 78.0) 72.0(64.0, 80.0) 0.098
MAP when left PACU, mmHg 84.0(79.0, 93.0) 86.0(81.0, 92.0) 0.654
SpO2 when left PACU, % 99.0(98.0, 99.0) 99.0(98.0, 99.0) 0.593
Postoperative hospital stays, day 3.00(3.00, 4.00) 4.00(3.00, 4.00) < 0.001

Note: Continuous data were presented as mean ± SD or median (the 25th percentile, the 75th percentile). Categorical variables were displayed in number (percentage). ED: emergence delirium; BMI: body mass index; MAP: mean arterial pressure; ASA: American Society of Anesthesiologists; HBP: high blood pressure; DM: diabetes mellitus; HR: heart rate; SpO2: oxygen saturation; PACU: post-anesthesia care unit; NRS: numerical rating scale; FESS: function endoscopic sinus surgery. A P-value < 0.05 indicates significant difference between the two groups